Futu News, February 10, this Thursday $LEPU BIO (02157.HK)$It was announced that it will issue about 127 million shares from February 10 to 15. The company plans to issue about 127 million shares, of which 12.688 million shares will be publicly sold and about 114 million shares will be sold internationally. The issue price per share is HK$687-7.38, and 1,000 shares per lot. It is expected to be listed on February 23.
Founded in 2018, Lepu Biotech is a biopharmaceutical company focusing on the field of cancer treatment. It has built multiple oncology product pipelines, with broad-spectrum anti-tumor drugs (mainly including anti-PD-1 antibody candidate products) as the backbone. ADC and oncolytic virus candidate drugs go hand in hand, thus maximizing the synergy between commercialization and drug efficacy.
As of the last practical date, there are eight clinical-stage drug candidates, three pre-clinical drug candidates, and a combination therapy of three clinical-stage drug candidates in the company's product pipeline. Among them, five of the eight clinical-stage drug candidates are targeted therapies, three are immunotherapy drugs, two of these three are immune checkpoint drugs and one is an oncolytic virus drug. As of the last practical date, the company has initiated 28 clinical trials, of which 3 have entered the registration phase and 2 are ongoing in the US.
In terms of financial data, the company currently does not generate any revenue from product sales. In 2019, 2020 and the first 8 months of 2021, the company recorded other earners...